

### Identification of Medicinal Products: Path to Global Implementation

#### Ron Fitzmartin, PhD, MBA

Sr. Informatics Advisor Office of the Director Center for Biologics Evaluation and Research

#### **Ta-Jen Chen** Project Management Officer Office of Strategic Programs Center for Drug Evaluation and Research

#### **Tyler Peryea**

Chemist Office of Health Informatics Office of Chief Scientist

#### Lawrence Callahan, PhD

Chemist Office of Health Informatics Office of Chief Scientist



## ISO Identification of Medicinal Products (IDMP)

### **Global PhPID and Dose Form Harmonization**

SBIA June 11, 2021

### What is IDMP

The Identification of Medicinal Product (IDMP) is a suite of five ISO standards that:


- Data elements and structure to uniquely and unambiguously identify medicinal product, Pharmaceutical Product, and substance
- common vocabularies for improved people communication
- common message standards for improved IT system communication

- ISO 11615 Medicinal Product Identification
- ISO 11616 Pharmaceutical Product Identification
- ISO 11238 Substance Identification
- ISO 11239 Pharmaceutical dose forms, units of presentation and routes of administration
- ISO 11240 Units of measurement

FD)

### **Key Benefits of IDMP**






 Cross-regions or global agreement on common substance ID and dose form is needed to maximize the benefits

### **Connecting Medicinal Products Together**

FDA



### **Concerns with the Current ISO Standard for PhPID**




### • PhPID Set

- ♦ PhPID\_Substance Level\_L1 → Substance(s) Term
- ♦ PhPID\_Substance Level\_L2 → Substance Term(s) +Strength+ reference strength
- ❖ PhPID\_Substance Level\_L3 → Substance Term(s) + Administrable Dose Form
- ❖ PhPID\_Substance Level\_L4 → Substance(s) Term+ Strength + reference strength + Administrable Dose Form
- Substance is the key for all PhPIDs
- A <u>global</u> Level 3 and 4 PhPID is not possible without a global consensus on Dose Form IDs

### **Concerns with the Current ISO Standard for Dose Form**

#### Pharmaceutical Product ID (PhPID)



Conceptual Representation of the Global PhPID Construction\*

\* Adapted from ISO TS 20451:2017

FDA


### Concerns with the Current ISO Standard for Dose For

### Region-to-Region Terminology Mapping is <u>Not</u> a Viable Solution

- Mapping results are based on a specified set of criteria and may be different region-toregion:
  - EDQM has 490 dosage forms<sup>1</sup>
  - FDA Terminology has 166 dosage forms<sup>2</sup>
  - Health Canada (HC) terminology has 170 dosage forms<sup>3</sup>
  - SNOMED has 213 dosage forms<sup>4</sup>
  - CDISC Terminology has 172 dosage forms<sup>5</sup>

- <sup>2</sup><u>https://evs.nci.nih.gov/ftp1/FDA/SPL/About.html</u>
- <sup>3</sup> https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-
- database/what-data-extract-drug-product-database.html
- <sup>4</sup><u>https://ncim.nci.nih.gov/ncimbrowser/</u>
- <sup>5</sup><u>https://www.cdisc.org/standards/terminology</u>

(Note: HC dosage form dataset for active products was downloaded and analyzed by FDA to determine the extent of 1:1 mapping)



<sup>&</sup>lt;sup>1</sup> <u>https://standardterms.edqm.eu/</u>).

### **UNICOM Gap Analysis Report**



### 4 Workshop results and suggesting gaps

- 4.1 Dose forms
- ... The adoption of this IDMP standard has been difficult, at times.
- -NCAs are in the process of implementing the standard in their own processes and **are facing backward compatibility issues**, because the granularity of terminologies varies frequently from EDQM.
- -The US FDA has shared its implementation difficulties, which are similar to those of the NCAs.


Source: Unicom - <u>https://unicom-project.eu/wp-content/uploads/2020/09/UNICOM\_Gap-Analysis.draft\_.v12-1.pdf</u>

### **Dose Form Characteristics Use Case for Global PhPID**



### • ISO 11239

-Six existing EDQM characteristics can be used to describe the pharmaceutical dose forms for use in global IDMP.



### **Dose Form Characteristics Examples for Global PhPID**




### Capsule – hard or soft

Pharmaceutical Dose Form	State of Matter	Basic Dose Form	Transformation	Release Characteristics	Intended Site	Administration Method
Capsule, Hard	Solid (0097)	Capsule (0051)	No Transformation (0042)	Conventional (0047)	Oral (0031)	Swallowing (0019)
Capsule, Soft	Solid (0097)	Capsule (0051)	No Transformation (0042)	Conventional (0047)	Oral (0031)	Swallowing (0019)
Capsule	Solid (0097)	Capsule (0051)	No Transformation	Conventional (0047)	Oral (0031)	Swallowing (0019)
Capsule, Gelatin Coated	(0097) Solid (0097)	(0051) Capsule (0051)	No Transformation (0042)	, , , , , , , , , , , , , , , , , , ,	(0031) (0031)	Swallowing (0019)

### **Dose Form Characteristics Example for Global PhPID**






- Group "like" medicinal Products in 'Capsule', 'Capsule, Hard', 'Capsule, Soft' Dose Form.
- This DF characteristics approach will allow the generation of global PhPID for all regions, without a central DF system.

### **Dose Form Characteristics for Global PhPID**



### Medicinal Products that Require Transformation are a Challenge



### **Dose Form Characteristics Use Case for Global PhPID**

FDA


Manufactured item Manufactured dose form: Powder for solution for injection Transformation:

Pharmaceutical product Administrable dose form: Solution for injection

Pharmaceutical Dose Form	State of Matter	Basic Dose Form	Transformation	Release Characteristics	Intended Site	Administration Method	Basic Admin. Dose Form
Powder (for solution) for injection	Solid (0097)	Powder (0066)	Dissolution (0040)	Conventional (0047)	Parenteral (0033)	Injection (0012)	Solution (0083)
Concentrate (for solution) for injection	Liquid (0099)	Concentrate	Dilution (0038)	Conventional (0047)	Parenteral (0033)	Injection (0012)	Solution
	Liquid	Solution	No Transformation	Conventional	Farenteral (0055)	Injection	Solution
(Solution) for injection	(0099)	(0083)	(0042)	(0047)	Parenteral (0033)	(0012)	(0083)

Used these 4 characteristics to generate of Global PhPID

### **Dose Form Characteristics Use Case for Global PhPID**



 PhPID groups "like" medicinal Products with same
 Administrable Dose
 Form; regardless of its'
 Manufactured Dose
 Form.

### WHO UMC-FDA Global PhPID Pilot

- narmaceutical Dose Form Characteristics for Global
- To evaluate using Pharmaceutical Dose Form Characteristics for Global Pharmaceutical Product Identification (PhPID)
- This pilot is limited to the use of core EDQM dose form characteristics and other potential characteristics for the generation of Global PhPID
- FDA assigns dose form characteristics for US marketed medicinal products based on 34 substances identified in the UNICOM Pilot
- UMC will generate corresponding PhPID using dosage form characteristics together with substance and strength
- FDA and UMC perform a data equivalency assessment on the use of characteristics for generation of PhPID and present to ISO TC215 WG6 in June 2021

### **Pilot Identified Some Challenges**

### Dose Form expression variations

Pfizer Covid-19 vaccine

- EMA *Dispersion* for Injection
- FDA *Suspension* for Injection
- UK *Solution* for Injection

# Prizer

### Strength expression variations – different units

- %, IU, mg/g or mg/mL
- AstraZeneca Covid-19 vaccine
  - EMA 2.5x10<sup>8</sup> *infectious units*
  - UK  $5 \times 10^{10}$  viral particles
  - Australia  $5 \times 10^{10}$  viral particles






### **Preliminary Results and Next Steps**

Generally, dose form characteristics as input to generation of PhPID is a viable solution.

A single organization, with global prospective, to consistently assign Dose Form Characteristics, strength, and substance ID may be important for global IDMP implementation

Proceed with the revision of ISO 11239/TS20440 and related IDMP standards with ISO TC215 WG6

### FDA IDMP Roadmap 2012-202x



FDA







### ISO 11238 and Global Substance Registration System(GSRS) SBIA Webinar (06/11/2021)





# **Organizing Information**

- FDA has the most important/valuable repository of human biological and product data but limited integration.
  - Submission process
  - Paper
  - PDF's
- IDMP is an effort to organize information on a global scale



# **Organizing Information**

- The amount of information is increasing
  - More drugs and vaccines on a global scale
  - Rapid Screening Methods
  - Enzyme and Receptor Profiling
  - CYP , Transporter and Receptor
  - Genomics
  - Epigenomics
  - Electronic Health Records
  - Many CMC changes




# **Global Medicinal Products**

- Medicinal/Pharmaceutical Product Marketplace is the most Global Marketplace
  - Highest Value Products
  - Highly regulated
  - Small Amounts of Material
    - Excipients often only a small proportion of market
  - Relatively Low Shipping Costs
  - Multiple ingredients from a variety of companies
    - Active
    - Excipients
    - Starting Materials
    - Packaging
    - Testing (Reference Standards)
    - Reagents



#### Figure 1: Manufacturing Sites of APIs for US Market by Country or Region (August 2019)



https://www.dcatvci.org/6213-global-api-sourcing-which-countries-lead



# Pharmaceutical Supply Chain

#### Figure 1





# **Organizing Information**

- Substances are one of the key lynchpins for organizing information
- Names are insufficient to describe substances
  - Same name different substances
    - Lime (fruit)
    - Lime (chemical)
  - Different names same substance
    - Acetaminophen
    - Paracetamol
- Define substances based on core scientific principles and assign a permanent Unique Ingredient Identifier (UNII)

### ISO 11238 Background



- ARISTOTLE (Metaphysics)...the generally recognizable substances... are the sensible substances, and sensible substances all have matter..., and in another sense the formula or form..., and thirdly the complex of matter and form, which alone is generated and destroyed, and is, without qualification, capable of separate existence
- A unit of matter that can be quantitatively measured
- Five types of substances
  - Chemicals, Proteins, Nucleic Acids, Polymers, and Structurally Diverse Material
  - Mixtures
- Substance are not defined based on use
- The same substance can be manufactured or isolated using different methods



### Substances (ISO IDMP)

- Five groups of elements are used to describe single substances.
  - Monodisperse
    - Chemicals
      - Defined primarily by molecular structure (connectivity and stereochemistry)
    - Proteins
      - Amino Acid Sequence, type of glycosylation, modifications
    - Nucleic Acids
      - Sequence, type of sugar and linkage, modifications



### Substances (ISO IDMP)

### Polydisperse

- Polymers (Synthetic or biopolymers)
  - Structural repeating units, type, geometry, type of copolymer (block or random), ratio of monomers, modifications, molecular weight or properties related to molecular weight, biological source for many biopolymers
- Structurally Diverse Substances (viruses, cells, tissues, complex materials)
  - Taxonomic, anatomical, fractionation, physical properties, modifications



### **Substances Scope**

- Active ingredients
- "Inactive" ingredients
- Impurities
- Metabolites
- Targets
- Off-targets
- Processing materials



### **Need for Specified Substance**


- Organize additional information on ingredients (SSG1).
  - Need to describe multiple substance ingredients (Simethicone, Colorants, Flavors)
  - Need to describe extracts (allergenic and herbal extracts, tinctures)
  - Need to distinguish materials that differ by physical form or critical properties (Polymorphs, Flowability, Compressibility)
  - Just starting to implement this at FDA



### **Need for Specified Substance**

- Need to tie material to a manufacturer and a process (SSG2 and SSG4)
- Need to tie material to a specific grade (SSG3)
- Need to obtain specification information (SSG4)
- Need to obtain information about processing materials (SSG4)
- Need to establish and monitor the supply chain (SSG2)
- Manufacturing and specifications were separated out in ISO version 2

### Specified Substance



FD/

### Specified Substance Implementation FDA

- Group 1 implemented will capture cell line data for recombinant proteins.
- Still working on how to capture the details of glycosylation at the Group 1 level
- Group 2 needs to agree on a common identifier for companies. (US Duns and FEI; EU:Org database)
- Specification module developed and an impurity module with USP is under development
- Manufacturing prototype has also been developed





**Global Substance Registration System** 

- Global marketplace for ingredients requires a global system to monitor the global supply chain
- A Global Repository of Regulatory Information and Data on Ingredients
- Help address shortages, substandard and counterfeit ingredients, coordinate inspections
- FDA with NIH has developed a software system that can be used by regulatory agencies throughout the world to register substances
- System being used by EMA, other European agencies and WHO-UMC
- Common system will make it easier to transfer data and allow international implementation






#### **Global Substance Identifier**

- IDMP specified the need for a global substance ID
- Global substance ID has not yet been agreed on
- Need a single organization needed to maintain a global substance
- Work with WHO-UMC underway for global substance ID
- Needed to implement PHPID
- Single organization to handle all of the Global Ids or a federated approach?

#### What is the GSRS?





GSR S

- Works in all modern browsers: IE, Chrome, and Firefox
- System freely distributed through NCATS with a large set of curated public domain data and updated periodically
  - Links to many outside resource (Chemid, Pubchem, Drug Bank, Orphan Drug, etc)
  - Structure and sequence-based searching
  - Faceted and advanced field-based searching
  - Data downloadable in a variety of formats JSON, Text, Excel
- Being used by EMA. Bfarm, WHO-UMC and CBG in Europe



#### **Current Status at FDA**

Approximately 200,000 thousand substances registered

- 120,000 Substances curated most publicly available
- Over 2,000,000 Names and Codes
- Nearly 200,000 Relationships Drug targets, Metabolites, Impurities
- Much of the data is public domain

# How it's used at FDA

- FDA has adapted GSRS to integrate with existing internal databases and systems.
  - Adverse events
  - Products (SPL)
  - Applications (INDs, NDAs)
  - Clinical Trials
  - In the future, GSRS can be used to facilitate digital submissions of formulation, quality and pharmacology data
  - Several classification systems
    - CFR DEA Classification





# In-vitro Clin Pharm Initiative

- Working with the Pistoia Alliance to develop data standards for in-vitro pharmacology data
- Scope of data determined
  - Metabolites
  - Metabolic Enzymes
  - Transporters
  - Receptors (Safety)
  - Ionic channels
  - Kinases
- Teams being set up
- Quick development in sync with GSRS



# **Vaccine Initiative**


- Vaccines are the most important public health tool we have
- No international nomenclature names vary significantly throughout the world
- WHO-UMC has set up a site for registration of Vaccine ingredients and related substances
- Used to workout common controlled vocabulary, possible global identifier
- Pilot Complete by September
- Industry involvement at some point

# **GSRS** Public Resources



- To get the software and data from and info from NCATS
  - <u>https://gsrs.ncats.nih.gov</u>
- NLM site for a list UNII codes
  - <u>https://fdasis.nlm.nih.gov/srs/srs.jsp</u>
- GInAS Meetings
  - Annual Meeting (USP, WHO-UMC, CBG have hosted)
- To Get on the GInAS Notification List
  - <u>https://gsrs.ncats.nih.gov</u>

# ginas (1) Working Collaboratively





#### Acknowledgements



#### FDA Team

Yulia Borodina, Larry Callahan, Ramez Ghazzaoui, Elaine Johanson, Samir Lababidi, Archana Newatia, Tyler Peryea, Frank Switzer, Annette Vernon, Alex Welsch

#### Foreign Regulatory Participants

Thomas Balzer (BFarM) Herman Diederik, Marcel Hoefnagel, Bert Kroes, Ciska Matai (MEB) Takeshi Misu, Izumi Oba (PMDA) Vik Srivastava, Craig Anderson (Health Canada) Philipp Weyerman (Swiss Medic) **Kew Gardens** Bob Alkins, Elizabeth Dauncey **USP** Fouad Atouf, Andrzej Wilk

WHO-UMC

Malin Jakobsson; Malin Flavid

#### NCATS Team

Dammika Amugoda, Niko Anderson, Trung Nguyen,, Tim Sheils; Dan Katzel; Mitch Miller; Noel Southall; Sarah Steman

#### **IDMP** Members

Paolo Alcini, Sabine Brosch, Tim Buxton, Ilaria Del Seppia, Panagiotis Telonis (EMA) Ta-Jen Chen, Ron Fitzmartin, Norman Schmuff, Mary Ann Slack, Randy Levin (FDA) Christian Hay (GS1) Pam Cafiero, Jean Fontaine, Surenda Gokhale, William Gregory, Barry Hammond, Manabu Inoue, Kostas Kidos, Andrew Marr, Vada Perkins, Wolfgang Spiegl (Industry) Paul Houston (EMA/CDISC)

#### EDQM

Claude Coune, Chris Jarvis (EDQM)

#### **Excipient Industry**

Dave Schonecker, Katherine Ulman





#### **GSRS Open Software** SBIA Webinar (06/11/2021)



Tyler Peryea Cheminformatician FDA/OC/OCS/OHI

**Collaboration With** 




National Center for Advancing Translational Sciences




- Outline
  - –What is it?
  - -How does it work?
  - -Where is it used?
  - -Where is it going?
  - -How to get involved?



- Freely distributable and open-source software
- Implementation of ISO 11238 standard
- Created and maintained by NIH/NCATS in collaboration with FDA and several other organizations








• What is it for?

GSRS Software is a self-contained **web application and database** for registering, storing, searching and exchanging substance information in a machine-readable form in compliance with the **ISO IDMP 11238** standard.

It is freely distributable and can be used as a local substance registration system by regulators, researchers and industry.

# FDA

### **GSRS** Software



Agreeing on Fundamentals Makes Everything Easier!

www.fda.gov




#### What is a substance?

A substance is a conceptual physical entity, which is capable of separate existence, and is uniquely definable based on its immutable chemical, physical and/or taxonomic properties.

Substance Type	Chemical Chemical Structure	Polymer Structural Repeat Unit(s)	Protein Amino Acid Sequence(s)	Nucleic Acid Nucleobase Sequence	Structurally Diverse	
Defined By					Taxonomic Information + Part	
Example	HO FO CH <sub>3</sub>	~[0~_] <sup>Юн</sup> А	>A35X00TA2K RCPGCGQGVQAGCPGGCVEE EDGGSPAEGCAEAEGCLRRE GQECGVYTPNCAPGLQCHPP 	>303159CVH9 TAAACGTTATAACGTT ATGACGTCAT	Organism Family     CANNABACEAE       Organism Genus     CANNABIS       Organism Species     SATIVA       Author     L,       Infraspecific Type     SUBSPECIES       Infraspecific Name     SUBSP. SATIVA	




Substance Type Percentage in INN Proposed Lists per Year



The kinds of substances being made as APIs are changing



• Registering a Substance






- Systematic
- Structured
- Machine-Readable
- Searchable
- Exchangeable



- Registration Tools
  - Data Entry Forms
  - Name-to-chemical structure tool
  - Image-to-chemical structure tool
  - Configurable validation rules
  - Uniqueness check algorithm
  - Audits and edit history




DEMO




FDA





# FDA





	Search		Q	Classic Site
Show JSON Import JSON	Advanced Features 👻		Validate an	
Overview				^
Registering New P	Protein Definition Level Complete	•	Deprecated	Access
Substance tags	$\searrow$			
Enter new tags (and press Enter after each entry) Definitional References 0	or select from suggested tags below			Create new 🕀 🗸 🗸
Names				Add Names 🕂 🗸 🗸
Protein Details				^
Protein Type 🔹 prot	ein subType	Sequence Origin	<ul> <li>Sequence Type</li> </ul>	- Access




- Browse & Search
  - Rich fielded text searches
  - Structure-based searching
  - RNA/Protein sequencebased searching
  - Customizable "facet" filters
  - Customizable data exports

Sub	stance Type	^	
Searc	h Substance Class	×	
🔲 St	ructurally Diverse	2581	
V Pr	otein	1339	
P	Modifications		^
N			
	Search Modifications		×
C C	No Modifications		2279
<u> </u>	Any Modification		1339
	Structural Modification		1308
	Agent Modification		54
	Physical Modification		3




- Other Tools
  - User Management
  - CV Management
  - Full REST API
  - Scheduled Jobs
  - Custom Triggers
  - Custom Reports







#### **Projects based on GSRS Open-Source Software**









#### **Development Timeline**






#### **GSRS 2.X Software Architecture**





#### **GSRS 3.X Software Architecture**





#### **GSRS 3.X Software Architecture**

# **GSRS** Public Resources



- Software Project site:
  - <u>https://gsrs.ncats.nih.gov/</u>
- GitHub Source Code:
  - <u>https://github.com/ncats/gsrs-play</u>
- To get on notification list:
  - <u>https://gsrs.ncats.nih.gov/</u>

#### Acknowledgements



50

#### FDA Team

Yulia Borodina, Larry Callahan, Ramez Ghazzaoui, Elaine Johanson, Samir Lababidi, Mitch Miller, Archana Newatia, Frank Switzer, Tyler Peryea, Annette Vernon, Alex Welsch

#### Foreign Regulatory Participants

Thomas Balzer (BFarM) Herman Diederik, Marcel Hoefnagel, Bert Kroes, Ciska Matai (MEB) Takeshi Misu, Izumi Oba (PMDA) Vik Srivastava, Craig Anderson (Health Canada) Philipp Weyerman (Swiss Medic) **Kew Gardens** Bob Alkins, Elizabeth Dauncey **USP** Fouad Atouf, Andrzej Wilk

WHO-UMC

Malin Jakobsson; Malin Flavid

#### NCATS Team

Dammika Amugoda, Marian Nkeng, Trung Nguyen, Daniel Katzel, Mitch Miller, Noel Southall, Sarah Stemann, Nikolaus Anderson, Jorge Neyra, Elizabeth Callahan

#### **IDMP** Members

Paolo Alcini, Sabine Brosch, Tim Buxton, Ilaria Del Seppia, Panagiotis Telonis (EMA) Ta-Jen Chen, Randy Levin, Mary Ann Slack (FDA) Christian Hay (GS1) Pam Cafiero, Surenda Gokhale, William Gregory, Barry Hammond, Manabu Inoue; Kostas Kidos, Andrew Marr, Vada Perkins, Wolfgang Spiegl (Industry) Paul Houston (EMA/CDISC)

#### EDQM

Claude Coune, Chris Jarvis (EDQM)

#### **Excipient Industry**

Dave Schonecker, Katherine Ulman

